drugset / Trial / NCT00440154
A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this study is to assess the effect of AVE5530 on LDL-C levels over a period of 4 weeks. The secondary objectives are to assess the effects of AVE5530 on other lipid plasma levels and the safety and tolerability of AVE5530.
Timeline
- Start
- 2007-02
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CANOSIMIBE | Small molecule | 5 mg | Oral |
| Subject | CANOSIMIBE | Small molecule | 25 mg | Oral |
| Subject | CANOSIMIBE | Small molecule | 50 mg | Oral |
| Subject | CANOSIMIBE | Small molecule | 100 mg | Oral |
| Comparator | Ezetimibe | Unknown | 10 mg | Oral |